FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
Go back to FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test| (NASDAQ: FRNM) | Delayed: 16.31 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.31 | 52 Week High | $ | |||
| Open | $16.31 | 52 Week Low | $ | |||
| Day High | $16.31 | P/E | N/A | |||
| Day Low | $16.31 | EPS | $ | |||
| Volume | 296 | |||||
